Valeritas

Valeritas is a pharmaceutical company specializing in the development of innovative peptide-based therapeutics aimed at treating metabolic and rare diseases. The company operates in the biopharmaceutical market, focusing on creating next-generation peptide medicines that address significant unmet medical needs. Valeritas serves patients suffering from conditions such as diabetes, congenital hyperinsulinism, and short bowel syndrome, among others. The business model revolves around research and development, advancing its proprietary peptide platform through various clinical stages, including Phase 3 trials for some of its key programs. Revenue is generated through the commercialization of its developed therapies, partnerships, and licensing agreements. The company is committed to transforming lives by providing advanced therapeutic solutions and has a robust pipeline of products in late-stage development.

Keywords: peptide therapeutics, metabolic diseases, rare diseases, diabetes, congenital hyperinsulinism, short bowel syndrome, Phase 3 trials, biopharmaceutical, proprietary platform, clinical development.